The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells

International Journal of Colorectal Disease

Volumn 27, Issue 11, 2012, Pages 1419-1428

  Kapral, Malgorzata ^a   Wawszczyk, Joanna ^a   Jurzak, Magdalena ^a   Hollek, Andrzej ^a   Weglarz, Ludmila ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Colon cancer; Inflammation; IP6; Metastases; Real time QRT PCR

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MESSENGER RNA; METALLOPROTEINASE; PHYTIC ACID; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER CELL; CELL STRAIN CACO 2; CONTROLLED STUDY; DOWN REGULATION; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MATRIX METALLOPROTEINASE 1 GENE; MATRIX METALLOPROTEINASE 10 GENE; MATRIX METALLOPROTEINASE 13 GENE; MATRIX METALLOPROTEINASE 2 GENE; MATRIX METALLOPROTEINASE 3 GENE; MATRIX METALLOPROTEINASE 9 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TISSUE INHIBITOR OF METALLOPROTEINASE 2 GENE; UPREGULATION;

CACO-2 CELLS; COLLAGENASES; COLONIC NEOPLASMS; GELATINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 3; METALLOPROTEASES; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHYTIC ACID; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84867991278     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1445-3     Document Type: Article

References (56)

1. Mantovani A, Garlanda C, Allavena P (2010) Molecular pathways and targets in cancer-related inflammation. Ann Med 42:161-170
2. Perwez Hussain S, Harris CC (2007) Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 12:2373-2380
3. Apte RN, Voronov E (2008) Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 222:222-241
4. Lewis AM, Varghese S, Hui Xu H, Alexander HR (2006) Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4:48
5. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9-34
6. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Rev 2:161-174
7. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153:893-904
8. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573
9. Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S (2004) Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1,-3, and-13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 19:518-524
10. Yamada T, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Inagaki D, Yamamoto N, Sato T, Fujii S, Numata K, Kunisaki C, Shiozawa M, Morinaga S, Akaike M, Rino Y, Tanaka K, Masuda M, Imada T (2010) Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res 30:2693-2699
11. Zhang M, Zhu GY, Gao HY, Zhao SP, Xue Y (2011) Expression of tissue levels ofmatrixmetalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. J Surg Oncol 103:243-247
12. von Lampe B, Barthel B, Coupland SE, Riecken E-O, Rosewicz S (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63-73
13. Heuschkel RB, MacDonald TT, Moneleone G, Baja-Elliott M, Walker Smith JA, Pender SLF (2000) Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesion of children with inflammatory bowel disease. Gut 47:57-62
14. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193
15. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727
16. Jiang Z, Goldberg ID, Shi Z (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245-2252
17. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases biological activity and clinical implications. J Clin Oncol 18:1135-1149
18. Duncan AM (2004) The role of nutrition in the prevention of breast cancer. AACN Clin Issues 15:119-135
19. Orzechowski A, Ostaszewski P, Jank M, Berwid SJ (2002) Bioactive substances of plant origin in food-impact on genomics. Reprod Nutr Dev 42:461-477
20. Ferguson LR, Harris PJ (1999) Protection against cancer by wheat bran: Role of dietary fibre and phytochemicals. Eur J Cancer Prev 8:17-25
21. Szwergold BS, Graham RA, Brown TR (1987) Observation of inositol pentakis-and hexakis-phosphates in mammalian tissues by 31P NMR. Biochem Biophys Res Commun 149:874-881
22. Matejuk A, Shamsuddin A (2010) IP6 in cancer therapy: Past, present and future. Curr Cancer Ther Rev 6:1-12
23. Jenab M, Thompson LU (1998) The influence of phytic acid in wheat bran on early biomarkers of colon carcinogenesis. Carcinogenesis 19:1087-1092
24. Norazalina WM, Hairuszah I, Norashareena MS (2010) Anticarcinogenic efficacy of phytic acid extracted from rice bran on azoxymethane-induced colon carcinogenesis in rats. Exp Toxicol Pathol 62:259-268
25. Shamsuddin AM, Vucenik I (2005) IP6 and inositol in cancer prevention and therapy. Curr Cancer Ther Rev 1:259-269
26. Vucenik I, Shamsuddin AM (2006) Protection against cancer by dietary IP6 and inositol. Nutr Cancer 55:109-125
27. Ferry S, Matsuda M, Yoshida H, Hirata M (2002) Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFκB-mediated cell survival pathway. Carcinogenesis 23:2031-2041
28. Bozsik A, Kökény S, Olah E (2007) Molecular mechanisms for the antitumor activity of inositol hexakisphosphate (IP6). Cancer Genomics Proteomics 4:43-51
29. Raina K, Rajamanickam S, Singh RP, Agarwal R (2008) Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res 14:3177-31784
30. Tantivejkul K, Vucenik I, Shamsuddin AM (2003) Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion migration and invasion of MDA-MB 231 human breast cancer cells. Anticancer Res 23:3671-3679
31. Kapral M, Wawszczyk J, Jurzak M, Dymitruk D, Wȩglarz L (2010) Evaluation of the expression of metalloproteinases 2 and 9 and their tissue inhibitors in colon cancer cells treated with phytic acid. Acta Pol Pharm 67:625-629
32. Rath T, Roderfeld M, Graf J, Wagner S, Vehr AK, Dietrich C, Geier A, Roeb E (2006) Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: A precancerous potential? Inflamm Bowel Dis 12:1025-1035
33. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: Trials and ribulations. Science 295:2387-2392
34. Fingleton B (2006) Matrix metalloproteinases: Roles in cancer and metastasis. Front Biosci 11:479-491
35. Vihinen P, Kähäri VM (2002) Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 99:157-166
36. Raddatz D, Bockemuhl M, Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: Relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17:547-557
37. Hussain S, Assender JW, Bond M, Wong LF, Murphy D, Newby AC (2002) Activation of protein kinase C zeta is essential for cytokine-induced metalloproteinase-1,-3, and-9 secretion from rabbit smooth muscle cells and inhibits proliferation. J Biol Chem 277:27345-27352
38. Xie Z, Singh M, Singh K (2004) Differential regulation of matrix metalloproteinase-2 and-9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J Biol Chem 279:39513-39519
39. Gan X, Wong B, Wright SD, Cai T-Q (2001) Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. J Interferon Cytokine Res 21:93-98
40. Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830
41. Bendardaf R, Buhmeida A, Ristamäki R, Syrjänen K, Pyrhönen S (2007) MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol 42:1473-1478
42. Westermarck J, Kähäri VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781-792
43. Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T (2001) Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 22:1035-1042
44. Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C (2009) Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: Effect on matrix metalloproteinases. Bioorg Med Chem 17:1290-1296
45. Salmela MT, Pender SLF, Karjalainen-Lindsberg M-L, Puolakkainen P, MacDonald TT, Saarialho-Kere U (2004) Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol 39:1095-1104
46. Kasaoka T, Nishiyama H, Okada M, Nakajima M (2008) Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. Clin Exp Metastasis 25:827-834
47. Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27:5287-5297
48. Castro MM, Tanus-Santos JE, Gerlach RF (2011) Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 64:567-572
49. Dejonckheere E, Vandenbroucke RE, Libert C (2011) Matrix metalloproteinases as drug target in ischemia/reperfusion injury. Drug Discov Today 16:762-778
50. Castro MM, Kandasamy AD, Youssef N, Schulz R (2011) Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases. Pharmacol Res 64:551-560
51. Cox TR, Erler JT (2011) Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Dis Model Mech 4:165-178
52. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101-117
53. Hu J, Van den Steen PE, Houde M, Ilenchuk TT, Opdenakker G (2004) Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with singlechain derivatives of a neutralizing monoclonal antibody. Biochem Pharmacol 67:1001-1009
54. Krzystyniak KL (2002) Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol Pharm 59:473-478
55. Huang C,MaWY, Hecht SS, Dong Z (1997) Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res 57:2873-2878
56. Kapral M, Parfiniewicz B, Strzałka-Mrozik B, Zachacz A,Weglarz L (2008) Evaluation of the expression of transcriptional factor NF-kappaB induced by phytic acid in colon cancer cells. Acta Pol Pharm 65:697-702